Ryvu Therapeutics :
Broad oncology pipeline generated from internal discovery engine, including kinase inhibitor, IO/immunometabolism and synthetic lethality programs. Lead compounds SEL120, a potential first in class CDK8 inhibitor for leukemias, lymphomas, and solid tumors in Ph 1b in AML and high-risk MDS (data expected in 2020), and SEL24, a first in class PIM/FLT3 kinase inhibitor in Ph 1/2 in AML (partnered with Menarini, data presented at EHA, June'20). Early stage pipeline addressing emerging solid tumor targets in oncology including SMARCA2/BMR, A2A/B, STING, HPK1, cancer metabolism.
Phase l or ll, Pre-Clinical Stage
Immuno-Oncology, Metabolic Disorders, Oncology
Gene Therapy, Small Molecule
Park Life Science
Top 10 Holders of Ryvu Therapeutics SA
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by